The chart of MRNA reveals a robust recovery over the past six months, surging over 90% from lows around $22 to highs near $59.55. This uptrend broke out of a multi-year downtrend channel that persisted since 2021 peaks above $450. However, the last 30 days have shifted to consolidation followed by a downside breakdown, with price declining over 3.5% monthly. A cup-and-handle formation and broken falling wedge suggested bullish continuation earlier, but recent price action has invalidated short-term upside, forming lower highs and testing prior consolidation zones. The broader quarterly trend remains constructive from deep lows, yet short-term structure points to distribution after the rally.
Critical support levels align around pivot points: S1 at $49.48, S2 at $48.78, and S3 at $47.87, coinciding with recent lows and the 52-week intermediate base. A hold above $47.87 could stabilize the pullback. Resistance begins at R1 $51.09, followed by R2 $52.00 and R3 $52.70, matching prior swing highs and the 20-day moving average cluster. These zones represent supply and demand imbalances where prior liquidity was absorbed, drawing trader attention for potential reversals or continuations.
Momentum has turned decisively bearish. The RSI(14) reading of 20.02 signals deeply oversold territory, often preceding bounces in oversold rallies. MACD(12,26) at -1.10 with a sell histogram confirms bearish divergence. Supporting oscillators include Stochastic(9,6) at 21.60 (sell), Williams %R at -100 (oversold), and CCI(14) at -121.76 (sell). ADX(14) above 50 indicates strong trend strength, but in the downward direction, underscoring the pullback's conviction.
MRNA trades below all simple and exponential moving averages, generating uniform sell signals. The 5-day SMA sits at $50.50, 20-day at $52.83, 50-day at $53.75, 100-day at $52.70, and 200-day at $52.05. This death cross-like alignment—shorter MAs below longer ones—reinforces the intermediate downtrend. Price action slicing through these levels has accelerated selling, though proximity to the 200-day SMA offers a potential dynamic support.
Trading volume averages 8.35 million shares daily, but recent sessions show lighter participation around 6 million, lacking conviction in the downside move. No significant spikes accompany the pullback, suggesting absence of panic selling. Earlier rally phases saw volume expansion on breakouts from falling wedges, but current contraction hints at consolidation potential rather than capitulation.
Tickeron’s AI Daily Buy/Sell Signals leverage artificial intelligence to scrutinize vast datasets including technical indicators, price patterns, and historical behaviors for MRNA. These signals identify potential buy or sell opportunities by detecting trends, momentum shifts, and pattern completions like breakouts or reversals. Traders rely on them to pinpoint entry/exit points, validate chart setups, and enhance decision-making amid volatile biotech swings. Updated daily, the AI models adapt to evolving market dynamics, offering an objective layer to traditional analysis. Explore the signals to align your strategy with data-driven insights.
Traders eye a potential oversold bounce if $47.87-$49.48 support holds, targeting resistance at $51.09-$52.70 for initial recovery tests. A breakdown below $47.87 could extend toward deeper supports near $42, aligning with prior consolidation lows. Monitor RSI for divergence, MACD histogram for crossover, and volume for pickup on any rebound. A close above $52 signals resumption of the prior uptrend; failure keeps bearish bias intact. Key levels and momentum shifts will dictate near-term direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with NVAX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then NVAX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | +11.97% | ||
| NVAX - MRNA | 54% Loosely correlated | +9.53% | ||
| BNTX - MRNA | 50% Loosely correlated | +1.19% | ||
| RGNX - MRNA | 49% Loosely correlated | +1.25% | ||
| PCVX - MRNA | 48% Loosely correlated | +2.97% | ||
| CRBU - MRNA | 47% Loosely correlated | +3.19% | ||
More | ||||